Cited by 501Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model OrganismsSirtuins and Resveratrol in Medicine

Strategies for targeting senescent cells in human disease

Open access
Gasek, Nathan S., Kuchel, George A., Kirkland, James L., Xu, Ming·2021·Nature Aging

Abstract

Cellular senescence represents a distinct cell fate characterized by replicative arrest in response to a host of extrinsic and intrinsic stresses. Senescence provides programming during development and wound healing, while limiting tumorigenesis. However, pathologic accumulation of senescent cells is implicated in a range of diseases and age-associated morbidities across organ systems. Senescent cells produce distinct paracrine and endocrine signals, causing local tissue dysfunction and exerting deleterious systemic effects. Senescent cell removal by apoptosis-inducing "senolytic" agents or therapies that inhibit the senescence-associated secretory phenotype, SASP inhibitors, have demonstrated benefit in both pre-clinical and clinical models of geriatric decline and chronic diseases, suggesting senescent cells represent a pharmacologic target for alleviating effects of fundamental aging processes. However, senescent cell populations are heterogeneous in form, function, tissue distribution, and even differ among species, possibly explaining issues of bench-to-bedside translation in current clinical trials. Here, we review features of senescent cells and strategies for targeting them, including immunologic approaches, as well as key intracellular signaling pathways. Additionally, we survey current senolytic therapies in human trials. Collectively, there is demand for research to develop targeted senotherapeutics that address the needs of the aging and chronically-ill.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43587-021-00121-8

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Senescent cells with a proapoptotic SASP survive a cytotoxic environment by upregulating pro-survival and antiapoptotic pathways such as SRC kinases, PI3K-AKT, HSP, serpines, mitochondrial pathways, and BCL-2-related proteins.

    “Through upregulation of pro-survival and antiapoptotic pathways such as SRC kinases, the PI3K-AKT signaling pathway, heat shock protein (HSP) pathways, serpines, mitochondrial pathways or apoptosis regulator BCL-2-related proteins, those senescent cells with a proapoptotic SASP can survive, despite the cytotoxic microenvironment they create6,7,14,34,35,54–58.”

    From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [58]

    The Cellular Senescence section says senescent cells avoid apoptosis by upregulating pro-survival pathways. The Modulating SCAPs section discusses Src kinase inhibition, PI3K/Akt, BCL-2-family proteins, mitochondrial apoptotic signaling and HSP90. The cited copy does not identify serpines as one of these pathways or specifically describe survival of cells with a proapoptotic SASP in a cytotoxic microenvironment; the SASP section instead discusses inflammatory effects and resistance to immune-mediated clearance. Page numbers are unavailable in our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Senescent cells in each pathological condition enhance the SASP autocrine loop.

    “but also enhance SASP autocrine loop, as found in multiple previous studies,124,125,126,127”

    From Single-cell senescence identification reveals senescence heterogeneity, trajectory, and modulators (2024) · cites this paper as [127]

    The Senescence-Associated Secretory Phenotype section says the SASP reinforces senescence through autocrine signaling and describes a feed-forward cycle involving increased SASP signals. It does not establish that senescent cells enhance this loop in every pathological condition; the section also notes that SASP effects vary by context. Page numbers were not provided in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Persistent senescent cells are known to exert detrimental long-term effects on organ function and can promote tumorigenesis.

    “Persistent senescent cells are known to exert detrimental long-term effects on organ function and can promote tumorigenesis33,96,112,177,178.”

    From COVID-19 and cellular senescence (2023) · cites this paper as [96]

  • Senescent cells are associated with aging and pathological conditions and can be targeted to slow the aging process.

    “Senescent cells are highly associated with aging and pathological conditions and could be targeted to slow the aging process.”
  • At the transcript level, p16 and p21 are the two most commonly used markers for senescent cells.

    “At the transcript level, p16 and p21 are the two most commonly used markers for senescent cells [3,16].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gasek, N. S., Kuchel, G. A., Kirkland, J. L., & Xu, M.
Affiliations
  • University of Connecticut (US)
  • Mayo Clinic (US)
Corresponding author
Xu, Ming
Venue
Nature Aging
Published
2021-10-07
Volume
1
Issue
10
Pages
870-879
ISSN
2662-8465 (ISSN-L)
OpenAlex
W3202997660
Cited by
501
References
152
Citations by year
2026: 78 · 2025: 120 · 2024: 141 · 2023: 95 · 2022: 63 · 2021: 4
FWCI
10.10
Type
journal article
Language
en
Open access
Locations
  • Nature Aging (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R21AG063528,R33AG061456, R37AG013925, R01AG072301, P01AG062413, R21AG063528,R03AG072374,R01AG066679, R01AG068860)
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
cellular senescence, senolytics, senescence-associated secretory phenotype, senolytic therapy, senotherapeutics, aging, age-related diseases, intracellular signaling, bench-to-bedside translation, chronic disease
MeSH terms
Senescence-Associated Secretory Phenotype, Aging, Cell Differentiation, Chronic Disease, Humans, Signal Transduction, Cellular Senescence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review